Examining the Role of Community Engagement in Enhancing the Participation of Racial and Ethnic Minoritized Communities in Alzheimer's Disease Clinical Trials; A Rapid Review

被引:0
|
作者
Dabiri, Sanaz [1 ,2 ]
Raman, R. [2 ]
Grooms, J. [3 ]
Molina-Henry, D. [2 ]
机构
[1] Univ Southern Calif, Sol Price Schaeffer Ctr, Los Angeles, CA 92121 USA
[2] Univ Southern Calif, Alzheimers Therapeut Res Inst, Los Angeles, CA 92121 USA
[3] Howard Univ, Dept Econ, Washington, DC USA
来源
关键词
AD/ADRD clinical trial; recruitment; minoritized; disparities; community-based; EFFECTIVE RECRUITMENT STRATEGIES; AFRICAN-AMERICAN; OLDER-ADULTS; SCALE DEVELOPMENT; DEMENTIA RESEARCH; KNOWLEDGE; INTERVENTION; POPULATIONS; INCREASE; CAREGIVERS;
D O I
10.14283/jpad.2024.149
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BackgroundDespite higher dementia prevalence in racial and ethnic minoritized communities, they are underrepresented in Alzheimer's disease clinical trials. Community-based recruitment strategies are believed to yield positive outcomes in various fields, such as cancer and cardiovascular clinical trials, but their outcomes in Alzheimer's disease and Related Dementias (AD/ADRD) require further study. In this systematic rapid review, we synthesized the available evidence on community-engaged recruitment strategies in enhancing participation in AD/ADRD clinical trials and observational study participation.MethodsWe searched and identified studies describing a community-based recruitment approach for racial and ethnic minoritized communities across seven databases (Pubmed, OVID MEDLINE, Cochrane Central Register of Controlled Trials, CINAHL, PsychINFO, Web of Science, and EMBASE).ResultsOut of 1915 screened studies, 49 met the inclusion criteria. Most studies employed multiple community-based recruitment approaches, including educational presentations, collaborations with community-based faith organizations, community advisory boards, and engagement with local clinics or health professionals. 52% of studies targeted more than one racial and ethnic minoritized population, primarily African Americans and then Hispanic/Latino. Gaps in knowledge about AD/ADRD, its increased risk among minoritized populations, distrust, and stigma were noted as barriers to research participation. Approximately 50% of the studies specified whether they evaluated their recruitment approaches, and in studies where approaches were evaluated, there was substantial heterogeneity in methods utilized.ConclusionThe quality of available evidence on the use of community-based recruitment approaches to include racial and ethnic minoritized populations in AD/ADRD research, particularly in clinical trials, is limited. Systematic assessment of recruitment strategies is urgently needed to increase the evidence base around community-engaged recruitment approaches.
引用
收藏
页码:1647 / 1672
页数:26
相关论文
共 50 条
  • [31] Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials
    Siemers, Eric
    DeMattos, Ronald B.
    May, Patrick C.
    Dean, Robert A.
    BIOMARKERS IN MEDICINE, 2010, 4 (01) : 81 - 89
  • [32] The Role of Clinical Trials in Preclinical Alzheimer's Disease Drug Development Programs
    Cummings, Jeffrey
    JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 2020, 7 (04): : 288 - 290
  • [33] Effectiveness of rivastigmine in Alzheimer's disease - Participation in trials should be based on clinical uncertainty, not enforcement
    Bullock, R
    Passmore, P
    Wilkinson, D
    Howard, R
    Jones, R
    BRITISH MEDICAL JOURNAL, 2000, 320 (7233): : 511 - 512
  • [34] The Role of Clinical Trials in Preclinical Alzheimer’s Disease Drug Development Programs
    Jeffrey Cummings
    The Journal of Prevention of Alzheimer's Disease, 2020, 7 : 288 - 290
  • [35] Stem Cell Therapy for Alzheimer's Disease: A Review of Recent Clinical Trials
    Kang, Jae Myeong
    Yeon, Byeong Kil
    Cho, Seong-Jin
    Suh, Yoo-Hun
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 54 (03) : 879 - 889
  • [36] Race reporting and disparities in clinical trials on Alzheimer's disease: A systematic review
    Canevelli, Marco
    Bruno, Giuseppe
    Grande, Giulia
    Quarata, Federica
    Raganato, Riccardo
    Remiddi, Francesca
    Valletta, Martina
    Zaccaria, Valerio
    Vanacore, Nicola
    Cesari, Matteo
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2019, 101 : 122 - 128
  • [37] Digital health technologies and Alzheimer’s disease clinical trials: might decentralized clinical trials increase participation by people with cognitive impairment?
    Victoire Leroy
    Wassim Gana
    Amal Aïdoud
    Jacques-Alexis N’kodo
    Anna-Chloé Balageas
    Pascal Blanc
    Dominique Bomia
    Camille Debacq
    Bertrand Fougère
    Alzheimer's Research & Therapy, 15
  • [38] Digital health technologies and Alzheimer's disease clinical trials: might decentralized clinical trials increase participation by people with cognitive impairment?
    Leroy, Victoire
    Gana, Wassim
    Aidoud, Amal
    N'kodo, Jacques-Alexis
    Balageas, Anna-Chloe
    Blanc, Pascal
    Bomia, Dominique
    Debacq, Camille
    Fougere, Bertrand
    ALZHEIMERS RESEARCH & THERAPY, 2023, 15 (01)
  • [39] Effectiveness of rivastigmine in Alzheimer's disease - Participation in trials should be based on clinical uncertainty, not enforcement - Reply
    Bentham, P
    Gray, R
    Raftery, J
    BRITISH MEDICAL JOURNAL, 2000, 320 (7233): : 512 - 512
  • [40] Role of Cerebrospinal Fluid Biomarkers in Clinical Trials for Alzheimer's Disease Modifying Therapies
    Kang, Ju-Hee
    Ryoo, Na-Young
    Shin, Dong Wun
    Trojanowski, John Q.
    Shaw, Leslie M.
    KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2014, 18 (06): : 447 - 456